ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
The ALLTogether1 clinical trial represents a significant advancement in the treatment of Acute Lymphoblastic Leukaemia (ALL) in children and young adults, with an estimated enrollment of 6,430 participants across multiple European countries. The trial's comprehensive master protocol aims to improve survival rates and reduce treatment-related toxicities through innovative risk stratification and targeted therapies. The involvement of major pharmaceutical companies such as Pfizer, Amgen, and Servier indicates strong industry interest and potential for collaboration. Given the high incidence of ALL and the ongoing need for improved treatment options, successful outcomes from this trial could lead to substantial market opportunities and competitive advantages for the involved sponsors and collaborators. The trial's design also allows for modular adaptations, which may facilitate rapid incorporation of new therapeutic agents as they become available.
Indication: Leukemia, Acute Lymphoblastic
Modality: small molecule
Target: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.
Sponsor: Mats Heyman
Source URL: ClinicalTrials.gov
Source updated: May 05, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.
View original source fields
Condition raw: Leukemia, Acute Lymphoblastic
Condition normalized: Leukemia, Acute Lymphoblastic
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.
Target normalized: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.